VIGEO THERAPEUTICS
Vigeo Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutic agents intended to treat an advanced malignant tumor that can effectively treat multiple types of cancer and improve the lives of patients. The company building a first-in-class drug discovery pipeline that reprograms the tumor immune microenvironment (TIME). They plan to commence multiple combination studies to evaluate VT1021 in combination with chemotherapies and/or anti-PD-1 antibodies. The company was established in 2011 and is headquartered in Cambridge, Massachusetts.
VIGEO THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2011-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.vigeotherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
617-945-0385
Total Funding:
10 M USD
Technology used in webpage:
Euro SPF Microsoft Exchange Online Office 365 Mail GoDaddy DNS GoDaddy
Similar Organizations
Aegerion Pharmaceuticals
Aegerion Pharmaceuticals engages in the development of therapeutics and pharmaceuticals to treat cardiovascular and metabolic diseases.
Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Apogenix
Apogenix is a biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases.
Biodel
Biodel is a biopharmaceutical company developing and commercializing therapeutics for the treatment of diabetes.
Cascadian Therapeutics
Cascadian Therapeutics is a bio-pharmaceutical company that researches, develops, and sells therapeutic products for treatment of cancer.
Cornerstone Therapeutics
Cornerstone Therapeutics is a pharmaceutical company focused on developing and commercializing products for the respiratory system.
Microbion
Microbion is a pharmaceutical company developing therapeutics for the treatment of bacterial infections.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Progenics Pharmaceuticals
Progenics Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for cancer patients.
Current Advisors List
Board_member
Current Employees Featured
Daniel Geffken Interim Chief Financial Officer @ Vigeo Therapeutics
Interim Chief Financial Officer
2017-11-01
Randy Watnick Co-Founder @ Vigeo Therapeutics
Co-Founder
Jim Mahoney Chief Executive Officer @ Vigeo Therapeutics
Chief Executive Officer
2021-02-01
Peter B. Finn Director @ Vigeo Therapeutics
Director
Founder
Investors List
Morningside Venture Investments
Morningside Venture Investments investment in Series A - Vigeo Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-21 | Vigeo Therapeutics Provides Clinical Update for Lead Asset VT1021 and Welcomes New Chief Executive Officer |
Official Site Inspections
http://www.vigeotherapeutics.com Semrush global rank: 13.19 M Semrush visits lastest month: 78
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 15.197.225.128
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Vigeo Therapeutics"
Overview - Vigeo
To provide financing for the development of its science and its organization, Vigeo has partnered with Morningside Venture Investments, Ltd, a private equity and venture capital firm founded in …See details»
Vigeo Therapeutics - Crunchbase Company Profile & Funding
Contact Email info@vigeotherapeutics.com Phone Number 617-945-0385 Vigeo Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutic agents intended to …See details»
Vigeo Therapeutics - LinkedIn
Vigeo Therapeutics | 849 followers on LinkedIn. It’s TIME to beat cancer. | Vigeo Therapeutics is a clinical stage company developing novel therapeutic agents for the treatment of cancer.See details»
Vigeo Therapeutics - PitchBook
Vigeo Therapeutics General Information Description. Developer of novel therapeutic agents designed to treat advanced malignant tumors. The …See details»
Pipeline - Vigeo
Our clinical program. Vigeo Therapeutics is an immunotherapy company focused on developing therapies to fight cancer and inflammation. Vigeo is a leader in understanding the important role endogenous Thrombospondin-1 (TSP-1) …See details»
Vigeo Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Vigeo Therapeutics, Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
Vigeo Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Www.vigeotherapeutics.com. Holding Company | 2011 | Massachusetts, United States | 10-50 | www.vigeotherapeutics.com. Last update 17 Apr 2025. Overview. Pipeline. Deal. Translational …See details»
Working At Vigeo Therapeutics: Company Overview and Culture
Vigeotherapeutics.com. Organization Type. Private. Social Media. Vigeo Therapeutics, Inc. operates in the healthcare industry focusing on biotechnology business. Based in Cambridge, …See details»
Vigeo Therapeutics - Overview, News & Similar companies
Jun 2, 2023 Vigeo Therapeutics contact info: Phone number: (617) 340-6073 Website: www.vigeotherapeutics.com What does Vigeo Therapeutics do? Based in Cambridge, MA, …See details»
Vigeo Therapeutics | Biotechnology, Health Care, Therapeutics
Vigeo Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutic agents intended to treat an advanced malignant tumor that can effectively treat multiple types …See details»
Vigeo Therapeutics - VentureRadar
Develops novel therapeutic agents for clinical stage cancer treatment, focusing on innovative approaches to improve patient outcomes. " Vigeo is currently developing therapies that target …See details»
Vigeo Therapeutics Company Profile | Management and
Smith@vigeotherapeutics.com: Vigeo Therapeutics Top Competitors. Company Employees Revenue Top technologies; Admunex Therapeutics Inc. 6: $1.3 M: Melior Discovery Inc. 32: …See details»
Vigeo Therapeutics, Inc.:Company Profile & Technical Research ...
Vigeo Therapeutics is a company that provides Medicine, Health care, Pharmacy and Therapeutics and more. Vigeo Therapeutics is headquartered in United States Massachusetts.See details»
Vigeo Therapeutics Revenue, Growth & Competitor Profile
Apr 7, 2025 Vigeo Therapeutics's Annual Report & Profile shows critical firmographic facts: What is the company's size? (Annual sales and employees) Vigeo Therapeutics's annual revenues …See details»
Overview - Vigeo
Oct 1, 2023 ONCOLOGY & INFLAMMATION . Oncology 4 ways to defeat cancer. Vigeo is focusing on tumors that are largely refractory to approved therapies. Our approach to drug …See details»
Vigeo Therapeutics Advances VT1021 Into Phase 2-3 …
Jan 20, 2022 For more information visit vigeotherapeutics.com or follow us on LinkedIn and Twitter. About Global Coalition for Adaptive Research (GCAR) ... (GCAR) is a 501(c)(3) …See details»
Vigeo Therapeutics, Inc. | European Clinical Trials Information …
Vigeo Therapeutics, Inc. is a biotechnology company that specializes in developing innovative therapies for cancer and oSee details»
Vigeo Therapeutics Company Overview, Contact Details
Mar 25, 2021 First.Last@vigeotherapeutics.com: John.Doe@vigeotherapeutics.com: 96%. First.L@vigeotherapeutics.com: John.D@vigeotherapeutics.com: 4%. See more formats. …See details»
Vigeo Therapeutics - Company Info, Employees & Competitors
View Vigeo therapeutics vigeotherapeutics.com location in 545 concord ave, cambridge, massachusetts, 2138, united states, revenue, industry and description. Find related and …See details»
Vigeo Therapeutics Provides Clinical Update for Lead Asset …
Sep 21, 2021 Phase 1/2 Dose Expansion Studies in Recurrent Glioblastoma and Pancreatic Cancer Completed; Results to be Reported at Key Medical Meetings During Q4 2021 …See details»